Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A Centers for Disease Control and Prevention committee voted to let Americans once again receive Johnson & Johnson's single-shot COVID-19 vaccine without any additional stipulations.

CDC panel recommends use of J&J's COVID vaccine, says benefits outweigh risks

A US medical panel has recommended resuming the use of the Johnson & Johnson COVID-19 vaccine.

US panel recommends resuming Johnson & Johnson COVID-19 vaccine

A CDC advisory panel on Friday recommended the U.S. resume using the Johnson and Johnson Covid-19 vaccine.

CDC panel recommends U.S. resume use of J&J Covid vaccine, saying benefits outweigh risks

Public health experts are recommending that the US resume using Johnson & Johnson's coronavirus vaccine, after immunizations were halted to investigate reports of rare blood clots. A Centers for Disease Control and Prevention advisory committee voted 10 to 4, with 1 abstention, on Friday that use of the shot should resume. US health regulators will now craft new language to be included along with the vaccine, warning of the risk of unusual clots in women under 50.

CDC panel says Johnson & Johnson's COVID-19 shot can be used again

JNJ is expecting revenue growth to come back strongly in FY21 after a pandemic-hit FY20 affected its consumer health and medical device divisions. The company is forecasting for a ~10-11% growth in reported sales and ~17%-19% increase in adjusted EPS of $9.42 - $9.57. As usual, management hiked the dividend by 5%.

Johnson & Johnson: Management Raises Guidance, Looks To Ignite Growth

"I think there's a huge amount of evidence that the benefit greatly outweighs this risk" when it comes to the J&J Covid vaccine, Dr. Wilbur Chen told CNBC.

Doctor on CDC advisory panel expects J&J Covid vaccine pause to eventually be lifted

Anthem

Costco

Nucor

Procter & Gamble

Tractor Supply

Ternium

Whirlpool

A great way to select dividend stocks is to find companies that are increasing the amount of their dividend payout. Here are eight stocks that have recently issued sizable dividend increases.

8 Dividend Stocks Increasing Payouts in 2021

The U.S. is expected to announce its decision on Johnson & Johnson's (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation probably with some restrictions, by today, reports Wall Street Journal. J&J vaccine injections were put on hold after reports of rare blood-clot cases, including one fatality.

JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ

A key CDC advisory committee is set to continue its discussion of the rare blood clots seen in a small number of patients who have received Johnson & Johnson's Covid-19 vaccine.

A CDC Committee Will Vote on J&J's Vaccine. What to Expect.

JNJ recently announced its vaccine rollout would resume in Europe. A vaccine glut could materialize shortly.

Johnson & Johnson Resumes Vaccine Rollout As Blood Clot Scare Subsides

Johnson & Johnson's (NYSE: JNJ) single-shot COVID-19 vaccine is expected to be imported to India for the fill and finish process over the next two to three months, according to a report by the Indian financial daily Mint. What Happened: JNJ is in talks with Indian pharmaceutical company Biological E.

Johnson & Johnson COVID-19 Vaccine Could Make Its Way To India By July

AbbVie

Many DGI investors have goals focused on income and growing the dividend stream. Their portfolio strategy should reflect these goals.

An Introduction To 'Buckets' For DGI Investors

The agency is set to meet on Friday to consider whether it is safe to resume the rollout of the Johnson & Johnson Covid-19 vaccine which was paused over safety concerns.

CDC Investigating New Death And Hospitalization Following Johnson & Johnson Vaccination

America's top public health experts are itching for one thing: more information. Ever since six cases of rare, but potentially life-threatening blood clots showed up in women who had recently been vaccinated with Johnson & Johnson's one dose COVID-19 vaccine, doctors and public health pros have been trying to determine whether this very, very rare event could be related to the shot.

5 experts who will vote on the fate of J&J's vaccine believe we should end the pause — and possibly add a warning for women

Shareholders at Johnson & Johnson approved Chief Executive Alex Gorsky's $29.6 million pay plan for 2020 at the healthcare company's annual general meeting on Thursday.

J&J shareholders approve CEO Gorsky's near $30 million pay plan

On Tuesday, Johnson & Johnson (NYSE: JNJ) reported $100 million in first-quarter sales of its single shot Covid-19 vaccine that's on hold in the U.S. due to a rare and potentially life-threatening blood clotting disorder which has been also related to AstraZeneca (NASDAQ: AZN) vaccine which still hasn't been approved for emergency use in the U.S. But on the financial side, the company exceeded Wall Street estimated both in terms of revenue and earnings. First-Quarter Figures Adjusted EPS amounted to $2.59 per share, exceeding the expected $2.34.

Johnson & Johnson's Vaccine Is On Hold But lts Businesses Emerged Healthier From The Pandemic

Target

Travelers

Walmart

There have been dividend increases left and right this month of April 2021.

Dividends Are Definitely Back - April 2021 Brings Roaring Dividends

A US plant that was making Johnson & Johnson's COVID-19 vaccine must fix a long list of problems including peeling paint and unsanitary conditions and practices to resume operation, according to a highly critical report by the Food and Drug Administration. Experts said addressing the issues raised in the scathing FDA inspection report could take months.

FDA finds peeling paint, debris at US plant making J&J's COVID vaccine

Emergent BioSolutions

The FDA concluded its inspection of Emergent BioSolutions Inc's (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped production on Monday. The agency released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training that caused ingredient mix-ups at the facility.

FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training

The report said the facility did not properly train personnel or adequately clean the warehouse.

FDA Issues Scathing Report Of Baltimore Warehouse Where Johnson & Johnson Vaccines Were Ruined

J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.

Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results

The statement comes after the U.S. Food and Drug Administration flagged problems, including peeling paint and loose debris, during inspections at a U.S. plant in Baltimore that makes the drugmaker's COVID-19 vaccine and asked for remediation of the issues.

J&J says supply chain for COVID-19 vaccine to include 10 sites

Shares of Emergent BioSolutions Inc. were up 1.3% in trading on Wednesday after the Food and Drug Administration said it inspected a plant in Baltimore that had been scheduled to begin producing Johnson & Johnson's COVID-19 vaccine after reports emerged of cross-contamination in vaccine production there. J&J confirmed several weeks ago that quality standards had not been met at the Emergent facility.

FDA inspection of Emergent's COVID-19 vaccine plant identifies 'potential quality issues'

The Food and Drug Administration said Wednesday a Baltimore plant that ruined millions of Johnson & Johnson Covid-19 vaccine doses was unsanitary and unsuitable to manufacture the shots.

News for Johnson & Johnson Stock (JNJ)